Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal Targets Anaphylm 12mg Exceeds Lower Bracket at All Expected Pivotal TargetsReports…
Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported…
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein…
PHOENIX, AZ / ACCESSWIRE / July 26, 2023 / The Stock Day Podcast welcomed CLS Holdings USA, Inc. (CLSH) ("the…
Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA…
Toronto, Ontario--(Newsfile Corp. - July 26, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased…
Toronto, Ontario--(Newsfile Corp. - July 25, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased…
The project aims to support selected companies as they go from major players to global powerhouses.TORONTO, ON / ACCESSWIRE /…
CHICAGO, IL / ACCESSWIRE / July 25, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global…